- Report
- January 2026
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2627EUR$3,000USD£2,280GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Report
- July 2025
- 200 Pages
United States
From €2181EUR$2,490USD£1,893GBP
Aricept is a drug used to treat Alzheimer's Disease, a progressive neurological disorder that affects memory, thinking, and behavior. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that is involved in memory and thinking. Aricept is the most commonly prescribed drug for Alzheimer's Disease, and is used to slow the progression of the disease and improve cognitive function. It is available in both immediate-release and extended-release forms, and is taken orally.
The Aricept market is highly competitive, with many companies offering similar products. Some of the major players in the market include Pfizer, Eisai, Novartis, and Mylan. Other companies such as Sun Pharmaceuticals, Teva Pharmaceuticals, and Dr. Reddy's Laboratories also offer generic versions of Aricept. Show Less Read more